Laura Housman leads Avalere’s Evidence & Strategy practice, applying her background in evidence generation, commercialization, and strategy to a broad range of client projects.

Before joining Avalere, Laura held a variety of leadership positions in industry and academia, including at Novartis where she led a team in access and health outcomes in support of molecular diagnostics and targeted therapies. Additionally, she founded Access Solutions Consulting, has led a national team in access, outcomes, and population health with Exact Sciences, and developed novel risk-sharing arrangements during her tenure at BlueCross BlueShield of Massachusetts.

Laura has a BA in economics, a Master of Public Health, and a Master of Business Administration from Boston University. She is currently a doctoral candidate in the School of Public Health at Boston University.

Authored Content


Ahead of the upcoming Asembia and ISPOR conferences, Avalere experts discuss the role of external assessors in value assessment.

This expert panel will address the challenge of integrating patient perspectives into value assessments, discussing implications for evidence strategy, health equity, caregiver involvement, and downstream impacts on care delivery.

With regulatory changes on the horizon, diagnostics stakeholders should prepare for a new evidence development and commercialization environment.

This spring, the FDA will issue a rule to begin regulating LDTs as medical devices. A multi-faceted legislative, legal and market response is anticipated.

Avalere analyzed the top trends in HEOR and key implications for life sciences companies to consider for future strategic planning.

Avalere experts dive into Trend #8: HEOR as a Differentiator vs. a Commodity and explore the need for tailored evidence generation planning.

In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #8: HEOR as a Differentiator Versus a Commodity.

ICER recently proposed piloting the GRACE framework in place of traditional cost-effectiveness analysis. We review the background of GRACE and its implications.

ChatGPT marked an AI inflection point decades in the making—with implications for health economics and outcomes research.

The FDA proposed to begin regulating LDTs as medical devices over the next 5 years. This has important implications for market dynamics and clinical care.

Avalere identified the top trends in HEOR and key implications for life sciences companies to consider for their 2024 strategic plans.

Avalere identified the top trends in health economics and outcomes research in 2023 and beyond. In this video, Avalere experts dive into a few of the key trends in HEOR that are significantly shaping the landscape.

In Part 2 of our video series on the negotiated drug list, Avalere experts discuss topics including effectiveness measures that will inform CMS’s maximum fair price determinations, evidence generation strategies for manufacturers with products that have been selected for negotiation, or that are eligible for selection in the future, and CMS’s definition of therapeutic alternatives.

Laura Housman, Avalere’s Evidence and Strategy Practice Director, discusses her past experience, trends in real-world evidence, and the role of data in advocating for the patient voice.

Delve into the far-reaching implications of the recently announced negotiated drug list as Avalere experts provide insights and answers to pressing questions surrounding CMS's landmark decision on Part D drug pricing and its impact on manufacturers, patients, and the future healthcare landscape.

Manufacturers should adjust commercial and evidence generation strategies in response to the shifted incentives under the IRA and Enhancing Oncology Model.

Sponsors with portfolio or pipeline assets within certain therapeutic areas can prepare for the downstream effects of price negotiation on the market.

New quality measures related to continuous glucose monitoring (CGM) were published in The Science of Diabetes Self-Management and Care by iDQI.

Ahead of the Asembia and ISPOR 2023 conferences, Avalere experts discuss the increasing importance of value and evidence strategies as part of Inflation Reduction Act (IRA) implementation planning.

IRA inflation rebates and drug price negotiation will impact drug launch prices in Medicare, with spillover effects in the Medicaid and commercial markets.

As CMS clarifies evidence requirements for drug price negotiations, manufacturers should prepare their strategies for asset development and on-market products.

On March 2, 2023, the Improving Diabetes Quality Initiative (iDQI) hosted a corporate roundtable to discuss the future of diabetes care and technology.

CMMI releases long-awaited response to President Biden’s executive order on drug pricing with a directive for the Centers for Medicare & Medicaid Services (CMS) to develop three models.

Avalere’s white paper draws on recommendations from a multi-stakeholder workshop to look at roadblocks and solutions for scaling sustainable solutions to address the diagnosis of rare disease.

Tune into another episode of Avalere Health Essential Voice. In this segment, we are joined by experts from nutrition service organizations to discuss the impact of medically tailored meals (MTM) on health outcomes and healthcare costs, and future opportunities to expand their reach through health insurance plans.

On November 3, the Journal of the Academy of Nutrition and Dietetics published an article entitled “Implementation Science in Evidence-Based Nutrition Practice: Considerations for the Registered Dietitian Nutritionist,” co-authored by Christina Badaracco.

Tune into our third episode in the Avalere Health Essential Voice podcast series focused on social determinants of health (SDOH). In this segment, our expert from Avalere’s Center for Healthcare Transformation is joined by officials from the Washington State Department of Health to discuss public health programs focused on maternal and child health, and how these programs relate to healthcare access and health outcomes.

With fewer eligible Americans participating in WIC, increased risk of food insecurity and decreased access to quality healthcare may place a greater burden on our healthcare system. The COVID-19 pandemic further exacerbates the challenges of vulnerable populations in access to food resources and routine and acute care.

Citing alarming statistics that nearly 1 of every 2 older Americans is at risk of malnutrition and that disease-associated malnutrition in older adults is estimated to cost nearly $53 billion annually, a broad group of advocates has presented a updated roadmap for a continuing national effort to help millions of Americans who suffer from malnutrition or could be at risk as they age. The expected rising incidence of malnutrition amidst the current COVID-19 pandemic makes it even more critical to advance solutions across all points of care.

On January 24, Avalere’s Christina Badaracco and Senior Advisor Wendy Everett published a piece in the Health Affairs blog highlighting the need to improve malnutrition care and provide possible pathways to a solution.

Various national and local health policies aim to address food insecurity through both healthcare and community-based programs.

A wide variety of health plans, provider networks, and national corporations have recently developed and announced innovations and strategies to expand access to healthcare and to address needs that promote health across communities.

Today, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association published appropriate use criteria (AUC) to guide the use of lumbar puncture (LP) and cerebrospinal fluid (CSF) analysis for use in the diagnosis of Alzheimer’s disease.

Tune into the second podcast in our series where Dr. Leslie Shaw, Professor of Pathology and Laboratory Medicine at the Pearlman School of Medicine at the University of Pennsylvania and Chair of the Workgroup that developed the Alzheimer’s Association’s appropriate use criteria for lumbar puncture and cerebral spinal fluid (CSF) testing in the diagnosis of Alzheimer’s disease, discusses how the Workgroup reviewed an extensive body of research on advances in CSF testing to develop the AUC.

Tune in to our podcast series as we explore the value of the newly released Alzheimer’s Association appropriate use criteria for lumbar puncture and cerebral spinal fluid (CFS) testing in the diagnosis of Alzheimer’s disease. We kick off this series with Dr. Maria Carillo, the Alzheimer Association’s Chief Science Officer and Dr. Jim Hendrix, Director of Global Science Initiatives.

The findings, published in The Journal of Endocrinology & Metabolism, will guide a pilot study to assess interventions to improve the identification and management of diabetes patients at high risk for hypoglycemia.

Avalere published an article this week on ASCO's plan to launch CancerLinQ™.

Listen to Avalere's Debbie Lucas explain the complex world of quality measurement.

In the Calendar Year (CY) 2015 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) final rule released on October 31, the Centers for Medicare & Medicaid Services (CMS) finalized a 2015 base per treatment rate of $239.43, up slightly from $239.02 in CY 2014.

Listen to Debbie Lucas discuss how quality measurement can lead to improvements in the quality of care and the impact on providers.

The use of quality and performance measures in public reporting, value-based purchasing, and alternative payment models is altering clinical practice by providing incentives to improve quality measures performance and provide high-value care. Debbie Lucas helps many stakeholders seek to understand these measures, assess their business impacts, and use the information to guide decision-making.

On Feb. 21, CMS enhanced the Physician Compare website to include the addition of quality measures to indicate the performance achieved on a set number of specific metrics.